xFusion Unveils Breakthrough High-Performance Computing Innovations at ISC 2025
HAMBURG, Germany, June 13, 2025--(BUSINESS WIRE)--xFusion International Pte. Ltd (xFusion) showcased its latest advancements in high-performance computing (HPC) and sustainable intelligent computing solutions at the International Supercomputing Conference (ISC) 2025, held from June 10 to 13 in Hamburg, Germany. As a global leader in HPC and computing infrastructure, xFusion highlighted its commitment to empowering industries and institutions with cutting-edge technologies that accelerate innovation and digital transformation.
Revolutionizing Computing with Innovative Solutions
At the Vendor Roadmap Session on June 12, Arthur Wang, Director of xFusion Computing Solution, delivered a compelling keynote titled "Innovative Computing with xFusion." Arthur emphasized the increasing demand for computing power in the age of AI and intelligent agents, as well as xFusion's role in addressing these challenges.
"The rise of intelligent agents has triggered an explosive demand for computing power. At xFusion, we are tackling this challenge head-on by pioneering advancements in HPC and intelligent computing technologies. From our FusionServer V8 series to our FusionPoD liquid-cooled cabinets, we are providing sustainable, efficient, and high-performance solutions to empower industries and institutions globally," said Arthur Wang.
Pioneering Green and Sustainable Data Centers
At exhibition booth, xFusion is demonstrating the deep integration of its computing technology with industry applications, drawing significant attention from attendees. To support the green and sustainable development of its customers' businesses, xFusion is leading the way with its FusionPoD rack-scale server. Designed for efficiency and energy savings, this system features an open architecture compatible with diverse computing power. Key features include:
High-Density: Supports up to 144 CPUs per cabinet.
Intelligent O&M: A tri-bus design for power, network, and liquid enables blind mating, improving O&M efficiency and supporting future robotic, unmanned operations.
100% Liquid Cooling: A native cold-plate liquid-cooling design, paired with a passive water-cooled rear door, achieves a pPUE as low as 1.06 and has earned the world's first TÜV SÜD certification for this technology.
Recently, xFusion partnered with Global Switch to rapidly deploy a liquid-cooled node at its Hong Kong data center, meeting stringent low-carbon requirements while delivering significant cost and efficiency benefits to the customer.
Accelerating HPC Application and Digital Transformation
The FusionOne HPC solution provides a viable path for industries such as scientific research and manufacturing simulation. Through deep hardware-software integration, the solution has been successfully deployed at institutions like the Poznan Supercomputing and Networking Center (PSNC), Istanbul Technical University, and Technische Universität Ilmenau to meet their growing research and educational demands.
To further accelerate enterprise digital transformation, xFusion offers:
FusionOne DFS (Distributed File System): A high-performance storage solution delivers unparalleled throughput, scalability, and efficiency for modern workloads. With up to 220GB/s read bandwidth, 125GB/s write bandwidth, and 5,700K IOPS, it handles massive workloads effortlessly. FusionOne DFS achieves 94.1% EC utilization, offering flexibility and reliability for the AI and HPC era.
FusionOne AI: A solution accelerates AI application deployment by combining computing, model, and application into a seamless, one-stop platform. Featuring open integration with third-party AI tools like LLaMA and Hugging Face, it simplifies GenAI deployment. Achieve 35% higher computing utilization with innovative GPU virtualization, including 1% GPU slicing for precise resource allocation. Built for scalability, FusionOne AI supports diverse workloads, from edge to cluster environments, ensuring smooth evolution and compatibility with mainstream CPUs and GPUs.
Driving the Era of Intelligent Computing
As the era of intelligent agents dawns, AI is fundamentally reshaping computing infrastructure. xFusion is seizing this opportunity to innovate on foundational technologies, collaborate with global partners, and accelerate the application of high-performance computing across all industries, ensuring that intelligent computing and digital energy can better serve everyone.
"At xFusion, we believe in combining cutting-edge technology with sustainability to create a smarter, more efficient future. Our three consecutive year participation at ISC 2025 underscores our commitment to driving the evolution of HPC and AI. In the future, xFusion will continue to innovate with partners through our xLAB, reshaping infrastructure to help enterprises in their digital and intelligent transformation and unlock the true value of computing," said Arthur Wang.
About xFusion
xFusion International Pte. Ltd. is a leading global provider of computing infrastructure and services. Driven by the vision "Let Computing Serve You Better," xFusion focuses on creating value for its customers and partners, accelerating digital transformation across a wide range of industries. Headquartered in Singapore, xFusion has a substantial global presence, including 9 research centers, 7 regional offices, and 6 Global Technical Assistance Centers (GTACs). xFusion's commitment to providing innovative computing solutions has enabled it to serve over 10,000 customers in more than 100 countries and regions, including the telecom, finance, internet, transportation, and energy sectors.
Official site: https://www.xfusion.com/en Case Center: https://www.xfusion.com/static/en/cases LinkedIn/X/Facbook/Youtube: xFusion Global
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612879566/en/
Contacts
information@xfusion.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
11 hours ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
12 hours ago
- Business Wire
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
13 hours ago
- Business Wire
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions
MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio' or 'the Company'), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. 'The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits,' said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. 'These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health.' OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass,' said Rob Myers, MD, Chief Medical Officer of OrsoBio. 'Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice Abstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO Mice Abstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice Abstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit
